Trend Brief
FDA Fronts Pivotal Life
Sciences Trend in 2020
The life sciences industry is experiencing a surge of scientific
and technology advances. However, there remains a sizeable
gap between the innovations and the technologies in order to
translate them into useful therapies. The U.S. Food and Drug
Administration (FDA) is endeavoring to close that gap with an
initiative to foster modernization in the life sciences industry —
beginning with its own technology infrastructure.
In 2019, the agency introduced its Technology Modernization
Action Plan (TMAP), a program designed to bring the
organization up to speed with the latest technologies in
order to expedite breakthrough discoveries with the intent
of improving public health.
1
This publication provides an in-depth look at the FDA's
transformation and addresses how the agency's initiative
will impact manufacturers of regulated products.
